NK Cell Symposium Krems
04. Mai 2023
Natürliche Killerzellen (NK) sind angeborene Lymphozyten, die in der Lage sind, bösartige Zellen abzutöten. Die angeborene Fähigkeit, transformierte Zellen zu lysieren, macht NK-Zellen zu einem attraktiven Instrument für die Krebsimmuntherapie.
NK Cell Symposium Krems
Das NK-Zell-Symposium bringt Forschungsgruppen zusammen, die sich auf das Verständnis verschiedener Aspekte der NK-Zell-Biologie konzentrieren.
Die Gruppen von Eva König (CCRI), Dagmar Gotthardt (VetMedUni) und Dagmar Stoiber-Sakaguchi (NK-Zell-Team unter der Leitung von Agnieszka Witalisz-Siepracka) werden ihre aktuelle Forschung vorstellen.
Der Höhepunkt des Symposiums ist der Vortrag von Dr. Dietmar Herndler Brandstetter, einem Experten für Tumorimmunologie.
Chairs: Pharmacology group
9.00-9.15 Opening
Session I
- 9.15-9.45: Theresa Harm - Uncovering NK cell checkpoints in triple negative breast cancer
- 9.45-10.15: Agnieszka Witalisz-Siepracka – The role of NK cells in myeloproliferative neoplasms
- 10.15-10.35: Clio-Melina Sperl - STAT3 in AML escape from NK cell surveillance
- 10.35-11.00: break
- 11.00-11.45:Key note speaker: Dietmar Herndler-Brandstetter – NK cell-targeted cancer therapy in humanized mice
Dietmar Herndler-Brandstetter studied Pharmacy at the University of Innsbruck. After he completed his PhD he continued his research at the University of Birmingham (UK) and further as a postdoctoral fellow in the laboratory of Richard A. Flavell at the University of Yale (USA). Since 2018 he is a group leader (Translational Tumor Immunology) at the Institute for Cancer Research at the Medical University, Vienna. His main interests cover the role of immune system in tumor development and metastasis as well as immune therapies.
12.00-13.00: Lunch
Session II
- 13.00-13.30 Julia List - The role of Ink4a/Arf in NK cell leukemia
- 13.30-13.50 Angela Hiesinger - Hyperactive STAT5B drives NK cell senescence
- 13.50-14.10 Sophie Huszarek - Pharmacological inhibition by CDK4/6 enhances NK cell cytotoxicity
14.10-14.45: Coffee break
Session III
- 14.45-15.15: Michelle Buri - Revealing unknown evasion mechanisms of leukemic cells from natural killer cells
- 15.15-15.45: Faith David - Finding novel molecular targets to improve natural killer cell-based therapies to treat leukemia
- 15.45-16.15: Hayeon Baik - The role of serine/threonine kinase 38 (STK38) in natural killer cells